GlassScriptPhysician profile
Seth M Kleinbeck
NPI 1912962143
$3,192.09
in general payments reported to CMS, 2019-2025
30 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $311 · 2021: $566 · 2022: $383 · 2023: $496 · 2024: $457 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,444.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $909.18 | 2021-2025 | |
| Pfizer INC. | $250.23 | 2019-2024 | |
| Glaxosmithkline, LLC. | $235.56 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $217.20 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.12 | 2019-2024 | Xifaxan, Trulance |
| Allergan, INC. | $184.82 | 2019-2020 | |
| Novo Nordisk INC | $143.49 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $134.66 | 2020-2025 | Breztri, Airsupra |
| Amgen INC. | $127.87 | 2019-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $81.58 | 2019-2024 | Verquvo, Belsomra, Lagevrio |
| Lundbeck LLC | $77.20 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $55.22 | 2019-2021 | |
| Dexcom, INC. | $53.02 | 2023-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $49.74 | 2019-2023 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $43.21 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $40.49 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.84 | 2024-2025 | Caplyta |
| Mylan Specialty L.P. | $39.22 | 2019-2024 | Yupelri |
| Esperion Therapeutics, INC. | $36.12 | 2020-2021 | |
| Eisai INC. | $35.29 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.91 | 2019-2025 | Jardiance |
| Ironwood Pharmaceuticals, INC | $29.85 | 2019-2021 | |
| Teleflex LLC | $28.37 | 2024 | Urolift |
| Biohaven Pharmaceuticals, INC. | $25.37 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.19 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $19.14 | 2022 | |
| Astellas Pharma US INC | $17.19 | 2021 | |
| Medtronic, INC. | $14.85 | 2025 | Intellis Adaptivestim |
| Sunovion Pharmaceuticals INC. | $13.79 | 2021 | |
| Genentech USA, INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Kleinbeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.